Bharat Biotech gets DGCI nod for intranasal Covid booster doses
The Drugs Controller General of India (DCGI) on Friday gave its permission to Bharat Biotech for conducting trials of intranasal booster doses against the coronavirus disease (Covid-19).
Related Posts
According to an input from news agency ANI, the trials will be held at nice different sites.
A day ago, the Hyderabad-based pharmaceutical company’s anti-Covid vaccine Covaxin was recently granted regular market approval for use in the adult population subject to certain conditions along with Serum Institute of India’s Covishield.